Product Specifications
| Catalog Number | BIC-5595E |
|---|---|
| Target | Epidermal growth factor |
| Target Symbol | EGF |
| Species | Human |
| Expression System | CHO |
| Expression Region | Asn971-Arg1023 |
| Molecular Weight | 6.2 kDa |
| Purity | ≥95%, by SDS-PAGE (under reducing (R) & Non-reducing conditions, visualized by Coomassie staining). |
| Endotoxin | ≤10 EU/mg by the LAL method. |
| Formulation | Lyophilized |
| Buffer | PBS, 5% Mannitol and 0.01% Tween 80, pH7.4. |
| Reconstitution | It is recommended to redissolve in sterile deionized water. |
| Storage & Stability | 36 months at -20°C to -80°C in lyophilized state; 6 months at -20°C to -80°C under sterile conditions after reconstitution; 7-10 days at 2°C to 8°C under sterile conditions after reconstitution; Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipping | The product is shipped with blue ice. |
| Lead Time | Products are in stock, but custom products may require further consultation. |
| Accession | P01133 |
| Alternative Names | Pro-Epidermal Growth Factor; EGF; Epidermal Growth Factor; Urogastrone |
Bioactivity
Recombinant Human EGF (Cat. No. BIC-5595E) stimulates proliferation of NIH3T3 cells. The ED50 for this effect ≤0.3 ng/mL. The acivity of BIC-5595E was equivalent to other competing products.
Quality Data
Human EGF (Cat. No. BIC-5595E) SDS-PAGE under reducing (R) & Non-reducing conditions.
Highly consistent bioactivity between different production batches of Recombinant Human bFGF (Cat. No. BIC-5595E) .

